3 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Aphasia, Primary Progressive: new trials by email Literature Review of Aphasia, Primary Progressive trials Research Report on Aphasia, Primary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| Communication Bridge 3 Study Communication Bridge™, Evidence-Based Impairment Focused - Primary Progressive Aphasia | Phase 2 | Recruiting | University of Chicago | 200 | 2024-08-23 | 2026-06-01 |
| Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia Active tDCS + Language Therapy, Sham tDCS + Language Therapy - Primary Progressive Aphasia, Logopenic Progressive Aphasia | Phase 2 | Recruiting | Johns Hopkins University | 180 | 2024-02-13 | 2026-05-05 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA) Transcranial Direct Current Stimulation (tDCS), Word-Naming Activity - Primary Progressive Aphasia | Phase 2 | Completed | NYU Langone Health | 11 | 2022-12-24 | 2024-09-19 |
| Dopaminergic Therapy for Frontotemporal Dementia Patients Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo - Frontotemporal Dementia, Dementia | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 75 | 2021-06-03 | 2024-10-22 |
| Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS high-definition transcranial direct current stimulation, modified constraint-induced language therapy - Primary Progressive Aphasia | Phase 2 | Completed | University of Pennsylvania | 76 | 2020-08-17 | 2026-10-19 |
Frontotemporal Dementia (5) · Aphasia (4) · Dementia (4) · Brain Diseases (2) · Central Nervous System Diseases (2) · Language Disorders (2) · Mental Disorders (2) · Nervous System Diseases (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Pick Disease of the Brain (2) · Alzheimer Disease (1) · Communication (1) · Communication Disorders (1)
Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Communication Disorders (7) · Neurobehavioral Manifestations (7) · Neurologic Manifestations (7) · Speech Disorders (7) · Brain Diseases (6) · Central Nervous System Diseases (6) · Language Disorders (6) · Mental Disorders (6) · Nervous System Diseases (6) · Neurocognitive Disorders (6) · Nutritional and Metabolic Diseases (6) · Frontotemporal Lobar Degeneration (5) · Metabolic Diseases (5)
Language Therapy (1) · Transcranial Direct Current Stimulation (1) · nabilone (1) · rotigotine (1)
AviadoBio Ltd (1) · EIP Pharma Inc (1) · I.R.C.C.S. Fondazione Santa Lucia (1) · Johns Hopkins University (1) · NYU Langone Health (1) · Simon Ducharme, MD (1) · University of Chicago (1) · University of Pennsylvania (1)
United States (6) · Canada (3) · Italy (2) · United Kingdom (2) · Belgium (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1)
Alessandro Martorana, MD, PhD (1) · Emily Roglaski, PhD (1) · Giacomo Koch, MD (1) · Kyrana Tsapkini, PhD. (1) · Leigh Charvet, PhD (1) · Martina Assogna, MD (1) · Roy H Hamilton, MD (1)
2023 (1), R01AG055425 (1), R01AG075111 (1)